New Releases from NCBI BookshelfAxicabtagene ciloleucel (DLBCL and HGBL, second line): Benefit assessment according to §35a SGB V, (expiry of the decision): IQWiG Reports – Commission No. A24-71 [Internet].​Axicabtagene ciloleucel (DLBCL and HGBL, second line): Benefit assessment according to §35a SGB V, (expiry of the decision): IQWiG Reports – Commission No. A24-71 [Internet].